The SAFE Pilot Trial—SAlvage Focal Irreversible Electroporation—For Recurrent Localized Prostate Cancer: Rationale and Study Protocol

• Published in: Frontiers in surgery 2022-06, Vol.9, p.900528-900528
• Main Authors: Marra, Giancarlo, Shah, Taimur T., D’Agate, Daniele, Marquis, Alessandro, Calleris, Giorgio, Lunelli, Luca, Filippini, Claudia, Oderda, Marco, Gatti, Marco, Valerio, Massimo, Sanchez-Salas, Rafael, Bossi, Alberto, Gomez-Rivas, Juan, Conte, Francesca, Deandreis, Desiree, Cussenot, Olivier, Ricardi, Umberto, Gontero, Paolo
• Format: Article
• Language: English
• Subjects: biochemical recurrence (BCR); focal treatment; irreversible electroporation (IRE); prostate cancer; PSMA-PET/CT; Surgery
• ISSN: 2296-875X; 2296-875X
• DOI: 10.3389/fsurg.2022.900528

IntroductionCurrently, the majority of prostate cancer (PCa) recurrences after non-surgical first-line treatment are managed with androgen-deprivation therapy (ADT). Salvage radical prostatectomy (sRP) is a curative alternative to ADT but yields significant morbidity. Preliminary evidence from focal salvage treatments shows similar oncological control but lower morbidity compared to sRP. Among available ablative focal energies, irreversible electroporation (IRE) is a treatment modality that proved promising, especially in treating apical lesions, where PCa most often recurs. Our aim is to test the safety of salvage IRE for recurrent PCa. MethodsWe performed a single-arm pilot feasibility study (IDEAL stage 2a): SAFE, SAlvage Focal irreversible Electroporation for recurrent localized PCa. Twenty patients with biopsy-proven PCa recurrence after primary non-surgical (radiation or ablation) treatment were included. All men will undergo mpMRI ± targeted biopsies, pre-operative PSMA-PET staging before inclusion and sIRE. Outcomes will be evaluated through internationally validated questionnaires and morbidity scales. All men will undergo a control biopsy at one year. ResultsPrimary objectives were the evaluation of the safety of sIRE (and patients' quality of life) after treatment. Secondary objectives were the evaluation of functional outcomes, namely, continence and erectile function changes and evaluation of short-term oncological efficacy. ConclusionsSAFE is the second pilot study to evaluate sIRE and the first one performed according to the most recent diagnostic and staging imaging standards. sIRE may provide a curative option for recurrent PCa together with lower comorbidities compared to sRP.